| Application no. and date | 04768282.8 (espacenet) (Federated) (European Patent Register), 20040902 | | Patent/reg. no. and date | DK/EP 1663236, 20090304 | | Publication date | 20060607 | | Priority no. and date | GB 0320806, 20030905 | | EP pub. no. and date |
EP 1663236 20060607 | | Effective date | | | Applicant/owner | AstraZeneca AB, S-151 85 Södertälje, SE | | Applicant ref. no. | AST 101213-1X | | Inventor | GALLAGHER, Neil, AstraZeneca R & D Alderley,
Alderley Park
Maccesfield,
Cheshire SK10 4TG, GB,
CURWEN, Jon Owen, Astra Zeneca R&D Alderley
Alderley Park
Macclesfield
Cheshire SK10 4TG, GB | | Representative | | | Opponent | | | IPC Class | A61K 31/497 (2006.01) , A61K 31/663 (2006.01) , A61K 31/675 (2006.01) , A61K 38/09 (2006.01) , A61P 35/00 (2006.01) | | Title | Kombination, der omfatter n-(3-methoxy-5-methylpyrazin-2-yl)-2-(4-[1,3,4-oxadiazol-2-yl]-phenyl)-pyridin-3-sulfonamid og et bihosphanat | | Int. application no. | GB2004003733 | | Int. publication no. | WO2005023264 | | Related patent (certificate) | | | Status | Bortfaldet | | Pædiatrisk forlængelse | - | | Udløbsdato for pædiatrisk forlængelse | - |
|
